Fig. 5From: Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysisThe forest figure of response rate (ORR, DCR) on MMR-MSI subgroup analysis. A ORR rate on MMR-MSI subgroup analysis. B DCR rate on MMR-MSI subgroup analysis. Objective response rate (ORR), disease control rate (DCR)Back to article page